COST-EFFECTIVENESS ANALYSIS OF MASS SCREENING PROGRAM FOR TYPE 2 DIABETES MELLITUS IN SOUTH KOREA
Author(s)
Jang S1, Park S2, Jo J1, Yang D1, Yoo S1, Bahk J1, Hahn S1, Lee T1
1Seoul National University, Seoul, South Korea, 2Seoul National University Hospital, Seoul, South Korea
OBJECTIVES: In spite of the national screening program, evidence is lacking on the health benefits such as decrease in complications and cost of screening of diabetes. Little is known about cost-effectiveness of national diabetes screening program. The purpose of this study is to evaluate cost-effectiveness of the current national screening program of type 2 diabetes in South Korea. METHODS: A Markov model for type 2 diabetes that reflected current national screening program was developed. This model analyzed the effects of screening for the population aged 40 and older with first and second FPG (fasting plasma glucose) tests. Data sources for the model parameters included the National Health and Nutrition Examination Survey data for cohort characteristics, the National Health Insurance claims data (HIRA-NPS) for costs, and published literature for other epidemiology data, treatment effects and utility pertaining to diabetes patients. From a payer’s perspective, cost per life-year gained (LYG) and cost per quality-adjusted life-year (QALY) gained from screening compared with no screening were calculated based on lifetime costs and accumulated LYGs and QALYs. One-way sensitivity analyses were carried out RESULTS: The incremental cost-effectiveness ratio (ICER) was higher than 84 million KRW per LYG and higher than 94 million KRW per QALY. The superior strategy in screening interval was identified as every two year. The results of sensitivity analysis showed that older age, higher participation rates of second FPG test, and higher rates of glucose control could improve cost-effectiveness of diabetes screening. CONCLUSIONS: The current national diabetes screening program was not cost-effective considering GDP per capita or willingness-to-pay per QALY. Policies to improve participation rates in second screening test need to be established since higher second screening rate leads to positive impacts on ICER and screening interval. Also, effective diabetes management program for diagnosed patients after screening is required as glucose control is related to ICER improvement.
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PHS60
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders